Fig. 3From: Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn’s diseaseIndividual serum concentration–time profiles of brazikumab. IV, intravenous; Q4W, every 4 weeks; SC, subcutaneousBack to article page